Cite
HARVARD Citation
Iqbal, R. et al. (n.d.). Evaluation of FES (16α-[18F]-fluoro-17β-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer. European journal of cancer. pp. S88-. [Online].